Skip Navigation

JNCI Journal of the National Cancer Institute 2004 96(3):235; doi:10.1093/jnci/djh033
© 2004 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Bojesen, S. E.
Right arrow Articles by Nordestgaard, B. G.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Bojesen, S. E.
Right arrow Articles by Nordestgaard, B. G.
Related Collections
Right arrowRelated Correspondence
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2004 Oxford University Press

CORRESPONDENCE

RESPONSE: Re: Integrin {beta}3 Leu33Pro Homozygosity and Risk of Cancer

Stig E. Bojesen, Anne Tybjærg-Hansen, Børge G. Nordestgaard

Affiliations of authors: Department of Clinical Biochemistry, Herlev University Hospital, Herlev, Denmark (SEB, BGN); The Copenhagen City Heart Study, Bispebjerg University Hospital, Copenhagen, Denmark (ATH, BGN); Department of Clinical Biochemistry, Rigshospitalet, Copenhagen University Hospital, Copenhagen (ATH).

Correspondence to: Børge G. Nordestgaard, MD, DMSc, Department of Clinical Biochemistry, Herlev University Hospital, Herlev Ringvej 75, DK-2730 Herlev, Denmark (e-mail: brno@ herlevhosp.kbhamt.dk)

The first 10% of the full text of this article appears below.

We thank Jin et al. for their comments and for providing more data on the importance of integrin {beta}3 Leu33Pro homozygosity for risk of cancer. In 9242 individuals, aged 20–95 years, sampled from the Danish general population and followed prospectively for 24 years, we observed a relative risk of all cancers in 33Pro/Pro homozygotes versus noncarriers of 1.4 (95% confidence interval [CI] = 1.1 to 1.9) (1. . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related Correspondence

Re: Integrin {beta}3 Leu33Pro Homozygosity and Risk of Cancer
Qianren Jin, Kari Hemminki, Ewa Grzybowska, Rüdiger Klaes, Magnus Söderberg, and Asta Försti
J Natl Cancer Inst 2004 96: 234-235. [Extract] [Full Text] [PDF]